Evidence map›Paper›PMID 40987557›Full record

GuidelineJournal of Zhejiang University. Science. B2025

A practice guideline for therapeutic drug monitoring of mycophenolic acid for solid organ transplants.

Shuang Liu, Hongsheng Chen, Zaiwei Song, Qi Guo, Xianglin Zhang, Bingyi Shi, Suodi Zhai, Lingli Zhang, Liyan Miao, Liyan Cui and 26 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of Zhejiang University. Science. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Shuang LiuDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Hongsheng ChenDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Zaiwei SongDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Qi GuoDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Xianglin ZhangDepartment of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China.
Bingyi ShiKidney Transplant Quality Control Center of National Health Commission, The 8th Medical Center of Chinese PLA General Hospital,, Beijing 100000, China.
Suodi ZhaiDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
Lingli ZhangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Liyan MiaoDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Liyan CuiDepartment of Laboratory Medicine, Peking University Third Hospital, Beijing 100191, China.
Xiao ChenDepartment of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Yalin Dong8Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Weihong GeDepartment of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Xiaofei HouDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Ling Jiang1Department of Pharmacy, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Long LiuDepartment of Urology, General Hospital of Northern Theater Command, Shenyang 110003, China.
Lihong LiuDepartment of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China.
Maobai LiuDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China.
Tao LinDepartment of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiaoyang Lu5Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Lulin MaDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Changxi WangOrgan Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
Jianyong Wu7Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Wei Wang8Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Zhuo Wang9Department of Pharmacy, The First Hospital Affiliated to Army Medical University, Shanghai 200433, China.
Ting Xu0Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China.
Wujun XueDepartment of Renal Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Bikui ZhangDepartment of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Guanren ZhaoDepartment of Pharmacy, The 8th Medical Center of Chinese PLA General Hospital, Beijing 100000, China.
Jun ZhangDepartment of Clinical Pharmacy, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
Limei ZhaoDepartment of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Qingchun Zhao6Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110003, China.
Xiaojian Zhang7Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yi ZhangDepartment of Pharmacy, Tianjin First Central Hospital, Tianjin 300192, China.
Yu ZhangDepartment of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Rongsheng ZhaoDepartment of Pharmacy, Peking University Third Hospital, Beijing 100191, China. zhaorongsheng@bjmu.edu.cn.

Funding

the Huatong Guokang Medical Research Fund 2023HT010the National Natural Science Foundation of China (NSFC) 72304007
6 · The paper itself

Abstract

Mycophenolic acid (MPA), the active moiety of both mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), serves as a primary immunosuppressant for maintaining solid organ transplants. Therapeutic drug monitoring (TDM) enhances treatment outcomes through tailored approaches. This study aimed to develop an evidence-based guideline for MPA TDM, facilitating its rational application in clinical settings. The guideline plan was drawn from the Institute of Medicine and World Health Organization (WHO) guidelines. Using the Delphi method, clinical questions and outcome indicators were generated. Systematic reviews, Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence quality evaluations, expert opinions, and patient values guided evidence-based suggestions for the guideline. External reviews further refined the recommendations. The guideline for the TDM of MPA (IPGRP-2020CN099) consists of four sections and 16 recommendations encompassing target populations, monitoring strategies, dosage regimens, and influencing factors. High-risk populations, timing of TDM, area under the curve (AUC) versus trough concentration (

Indexed as

Drug MonitoringImmunosuppressive AgentsMycophenolic AcidOrgan TransplantationDelphi TechniqueHumansImmunosuppressive AgentsMycophenolic AcidGrading of Recommendations Assessment, Development, and Evaluation (GRADE)GuidelineMycophenolic acid (MPA)Solid organ transplantTherapeutic drug monitoring (TDM)

Identifiers

PMID40987557
PMCPMC12456993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.